Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2023-04-21 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
中信建投证券股份有限公司关于科兴生物制药股份有限公司2022年度募集资金存放及使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities company (中信建投证券股份有限公司) acting as the sponsor for 科兴生物制药股份有限公司 regarding the 2022 annual special audit of the company's raised funds deposit and actual usage. It includes detailed financial figures about the raised funds, their management, usage, storage, and compliance with regulatory requirements. The document references regulatory guidelines related to raised funds management and includes an auditor's opinion on the compliance and accuracy of the report. The content is focused on the management and use of capital raised through an IPO and subsequent investment projects, which aligns with a specialized audit or verification report rather than a full annual report or earnings release. It is not a simple announcement or a brief summary but a comprehensive audit-related report on the use of raised funds. Therefore, the document fits best under the category of Audit Report / Information (AR). FY 2022
2023-04-21 Chinese
2022年度募集资金存放及实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company in 2022. It references regulatory guidelines related to the management and use of raised funds, includes detailed financial figures about the raised capital, its allocation, bank accounts, and usage status. The document is titled as a "专项报告" (special report) on the storage and actual use of raised funds for the year 2022. It does not present a full annual report or interim financial statements, nor is it an announcement or certification. It specifically focuses on the use and management of capital raised, which aligns with the category of Capital/Financing Update (CAP).
2023-04-21 Chinese
2022年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2022年度董事会审计委员会履职情况报告" which translates to the "2022 Annual Board Audit Committee Performance Report." It details the audit committee's activities, meetings, evaluations of external auditors, review of financial reports, internal audit guidance, and internal control assessments for the year 2022. The document is a report on the audit committee's work and oversight related to the company's financial reporting and internal controls. It is not a full annual report (10-K) but rather a specific audit committee report. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and related information. The document length is 2386 characters, which is consistent with a detailed committee report rather than a brief announcement. Therefore, the classification is AR with high confidence. FY 2022
2023-04-21 Chinese
独立董事关于第二届董事会第五次会议相关议案的意见
Board/Management Information Classification · 95% confidence The document is a detailed independent directors' opinion on various board meeting agenda items, including internal control evaluation, profit distribution plan, fundraising usage report, executive compensation, stock issuance authorization, and stock incentive plan adjustments. It is related to the company's board meeting (second board's fifth meeting) and contains opinions on management proposals rather than financial statements or earnings data. The content focuses on governance, internal controls, and management decisions rather than financial results or audit reports. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management activities.
2023-04-21 Chinese
关于召开2022年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2022 Annual General Meeting (AGM) of the company, including details such as the date, voting methods, agenda items, and instructions for shareholders to attend and vote. It does not contain the actual annual report or financial statements but rather informs shareholders about the meeting where such reports will be discussed and voted on. The document length is 3549 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as AGM Information (AGM-R).
2023-04-21 Chinese
2022年内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制评价报告' which translates to '2022 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022, including financial and non-financial internal control defects, standards for defect recognition, and rectification status. The content is focused on internal control evaluation rather than full financial statements or annual performance. It is a standalone report on internal control evaluation, not a full annual report or audit report. This fits the definition of an Audit Report / Information (AR), which includes audit reports and applied accounting principles but excludes full annual reports. The document length is 3875 characters, which is sufficient for a detailed report but not a brief announcement. Therefore, the classification is AR with high confidence. FY 2022
2023-04-21 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.